Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
26 hedge funds and large institutions have $34.8M invested in Interpace Biosciences, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 2 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
5% less capital invested
Capital invested by funds: $36.5M → $34.8M (-$1.74M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$649K |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$155K |
| 3 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
+$52.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.9K |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$41.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Leonard Capital Management
Vero Beach,
Florida
|
-$717K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$56.6K |
| 3 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
-$32.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$28.6K |
| 5 |
Renaissance Technologies
New York
|
-$27K |
IDXG Hedge Fund Activity: Q1 2014 in Review
26 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2014, worth a combined $34.8M — down 4.8% from $36.5M a quarter earlier.
Fund positioning in IDXG was balanced in Q1 2014: 2 funds opened new positions, 2 closed out, 7 added to existing stakes and 5 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $649K. The largest seller was Leonard Capital Management, exiting entirely with an estimated $717K sold.
- 26 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2014, unchanged from Q4 2013.
- Funds reported $34.8M of Interpace Biosciences, Inc. Common Stock stock for Q1 2014, down 4.8% quarter-over-quarter.
- 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2014 and 2 closed out, a net change of 0 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2014 was Dimensional Fund Advisors, an estimated $649K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2014 was Leonard Capital Management, an estimated $717K sold.
Based on aggregated 13F filings for Q1 2014.